ANTI-SLC13A5 CLONE 1D4 ZOOMAB« RABBIT MONOCLONAL (C15-1669-629)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1D4 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects Na(+)/citrate cotransporter (SLC13A5). It targets an epitope within 20 amino acids from the C-terminal half.

Immunogen

KLH-conjugated linear peptide corresponding to 20 amino acids from the C-terminal half of human Na(+)/citrate cotransporter (SLC13A5).

Application

Quality Control Testing

Evaluated by Western Blotting in Mouse liver tissue lysates.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected SLC13A5 in Mouse liver tissue lysates.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected SLC13A5 in Human liver tissue lysates and His/ABP-tagged recombinant fragment of Human SLC13A5.

ELISA Analysis: A serial of dilutions from a representative lot detected recombinant Human SLC13A5.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected SLC13A5 in HepG2 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected SLC13A5 in Human liver tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound SLC13A5 peptide with a KD of 1.5 x 10-6 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Target description

Na(+)/citrate cotransporter (UniProt: Q86YT5; also known as NaCT, Sodium-coupled citrate transporter, Sodium-dependent citrate transporter, Solute carrier family 13 member 5) is encoded by the SLC13A5 (also known as NACT) gene (Gene ID: 284111) in human. SLC13A5 is a multi-pass membrane protein with twelve transmembrane domains. It serves as a high-affinity sodium/citrate co-transporter that mediates the entry of citrate into cells. It functions in various metabolic processes in which citrate plays a critical role, including the energy production and fatty acid synthesis. It transports citrate into the cell in a Na+-dependent manner, recognizing the trivalent form of citrate (physiological pH) rather than the divalent form. It can also recognize succinate as a substrate, but its affinity for succinate is several folds lower than for citrate. SLC13A5 is highly expressed in brain neurons and its loss can lead to encephalopathy and pharmacoresistant seizures. Mutations in SLC13A5 gene are known to cause developmental and epileptic encephalopathy 25, an autosomal recessive disorder that is characterized by subclinical seizures appearing in the first days of life, evolving to severe epileptic disease. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kumar, A., et al (2021). Cell Rep. 36; 109701; Henke, C., et al. (2020). Neurobiol Dis 143; 105018).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.